经皮免疫接种合成病毒样颗粒可有效增强呼吸道合胞病毒保护性免疫
该临床前研究在小鼠中评估了经皮贴片递送展示多个RSV F蛋白位点II模拟表的合成病毒样颗粒疫苗V-306的加强免疫效果。结果显示经皮加强免疫可显著增强先前皮下接种V-306诱导的免疫应答,包括F和FsII特异性抗体增加、竞争palivizumab并结合中和RSV,且鼻内RSV攻击后肺部病毒复制显著降低,未诱导增强性RSV疾病。
要点
- 经皮加强V-306可显著增强小鼠既有的RSV免疫应答。
- 加强后F和FsII特异性抗体增加,可竞争palivizumab并中和RSV。
- 经皮加强后RSV攻击小鼠肺部病毒复制显著降低,无增强性疾病。
核心结论
- 基于V-306的经皮加强疫苗在小鼠中安全且有效增强既有的RSV免疫。
- 该无针疫苗候选可能适用于孕妇(保护婴儿)和老年人的加强免疫。
研究设计与样本
- 临床前小鼠研究,评估经皮贴片递送展示多个RSV F蛋白位点II模拟表的合成病毒样颗粒疫苗V-306作为加强免疫。
- 小鼠先前经皮下接种同源V-306诱导免疫,再经皮加强,随后进行鼻内RSV攻击。
主要发现
- 经皮加强V-306显著增加F和FsII特异性抗体,可竞争palivizumab结合靶抗原并中和RSV。
- 经皮加强V-306显著降低实验小鼠鼻内RSV攻击后的肺部病毒复制。
- 经皮加强V-306未诱导增强性RSV疾病。
临床怎么用
- 经皮无针加强疫苗策略可能适用于孕妇(通过母体抗体被动转移保护新生儿)和老年人的RSV加强免疫。
局限性
- 证据来自小鼠临床前研究,尚未在人体中验证安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the substantial health and economic burden caused by RSV-associated illness, no vaccine is available. The sole licensed treatment (palivizumab), composed of a monoclonal neutralizing antibody, blocks the fusion of the virus to the host cell but does not prevent infection. The development of a safe and efficacious RSV vaccine is therefore a priority, but also a considerable challenge, and new innovative strategies are warranted. Most of the adult population encounter regular RSV infections and can elicit a robust neutralizing antibody response, but unfortunately it wanes over time and reinfections during subsequent seasons are common. One approach to protect the mother and young infant from RSV infection is to administer a vaccine capable of boosting preexisting RSV immunity during pregnancy, which would provide protection to the fetus through passive transfer of maternal antibodies, thus preventing primary RSV infection in newborns during their first months of life. Here, we describe the preclinical evaluation of an epicutaneous RSV vaccine booster that combines epicutaneous patches as a delivery platform and a Synthetic Virus-Like Particles (SVLP)-based vaccine displaying multiple RSV F-protein site II (FsII, palivizumab epitope) mimetic as antigen (V-306). We demonstrated in mice that epicutaneous immunization with V-306 efficiently boosts preexisting immunity induced by the homologous V-306 administered subcutaneously. This boosting was characterized by a significant increase in F- and FsII-specific antibodies capable of competing with palivizumab for its target antigen and neutralize RSV. More importantly, epicutaneous booster immunization with V-306 significantly decreased lung viral replication in experimental mice after intranasal RSV challenge, without inducing enhanced RSV disease. In conclusion, an epicutaneous booster vaccine based on V-306 is safe and efficacious in enhancing RSV preexisting immunity in mice. This needle-free vaccine candidate would be potentially suited as a booster vaccine for vulnerable populations such as young infants via pregnant women, and the elderly.
引用
- Hervé PL, Dhelft V, Zuniga A, et al. Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus. Vaccine. 2021. PMID: 34154864. doi:10.1016/j.vaccine.2021.03.081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。